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Objectives: The New Medicine Service (NMS) is a national community pharmacy 
service to support medicines-taking in people starting a new medicine for defined 
long-term conditions. The study investigated the expansion of NMS for patients with 
gout newly prescribed allopurinol as urate lowering therapy(ULT). Non-adherence 
with ULT is > 60% in the UK MethOds: A probabilistic cost-effectiveness analysis 
from a NHS perspective was conducted to compare NMS (two follow-up consul-
tations to identify and resolve medicines problems) with standard practice (SP) 
(usual supply without further follow-up).Treatment success was defined as patients 
reaching serum-uric-acid-levels < 6mg/dL (sUA-controlled). A Markov model was 
developed to generate incremental cost-effectiveness ratios (ICER). Three health-
states were included: sUA-controlled; sUA-uncontrolled; death. sUA-uncontrolled is 
associated with more acute gout attacks, higher mortality and is more likely in non-
adherent patients. Cycle length was 1 year with a life-time horizon. Transition prob-
abilities, resource use and utilities were derived from published studies. Costs and 
utilities were discounted at 3.5%. The results were plotted on an ICER-scatter-plane 
and presented as a cost-effectiveness acceptability curve (CEAC). Results: mean 
(95% CI) cost per patient- NMS: £2569.43 (2203.69, 2935.17); SP: £2595.39 (2229.63, 
2961.14) and mean (95% CI) QALYs generated per patient- NMS: 10.39 (10.10, 10.68) 
SP: 10.34(10.06,10.60) suggested that NMS dominated SP with increased QALYs (0.058 
(-0.0008, 0.1168)) and reduced costs (-£25.96 (-81.37, 29.44). There was a 83.3% prob-
ability that NMS dominated SP and 98.4% probability that NMS was cost-effective 
at £20000 per QALY ceiling willingness-to-pay. cOnclusiOns: NMS appears to be 
cost-effective when initiating ULT. It was assumed NMS would increase ULT adher-
ence by 11% as in other diseases. NMS remained dominant down to an adherence 
increase of 5.4%. Reasons for ULT nonadherence matched the intervention design 
but further work is needed to assess the actual effectiveness of NMS in ULT.
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bAckgROund: Compliance to therapy is a widespread public health concern espe-
cially for chronic diseases, such as osteoporosis, as it is associated with increased 
morbidity and mortality due to fragility fractures. Objectives: To conduct the sys-
tematic review of clinical trials evaluating adherence to oral and parenteral bispho-
sphonates in patients with postmenopausal and senile osteoporosis. MethOds: 
We searched publications in PubMed and the Cochrane Library in November 2014. 
Studies of any design published in English were considered. The following criteria 
of medication adherence were taken into account: persistence rate (percentage 
of patients remaining on therapy at a given time). compliance rate (percentage 
of patients act in accordance with the prescribed interval and dose of a dosing 
regimen), medication possession ratio (proportion of doses dispensed in relation 
to doses prescribed), persistence (number of days from initiation to discontinuation 
of therapy). Results: Thirty one publications were included (1 meta-analysis, 5 
systematic reviews, 14 RCT, 7 prospective cohort studies, and 4 retrospective cohort 
studies). Original studies were heterogeneous in terms of drugs, treatment regimes, 
follow up periods, and measurements of adherence, so quantitative meta-analysis 
was not possible. The 12 months persistence rate for patients receiving oral bis-
phosphonates varies in the range of 16-78% in real practice and 54-88% in RCT. The 
persistence rate for parenteral bisphosphonates at 12 months was 86% in one real 
practice study, and 95% in one RCT. cOnclusiOns: Methodology of evaluating 
compliance/adherence or persistence is heterogeneous among the studies of bis-
phosphonates treatment in patients with osteoporosis. Сompliance and persistence 
with bisphosphonates are poor and suboptimal in real practice. The parenteral 
administration of bisphosphonates seems to have enhanced adherence when com-
pared with oral bisphosphonates.
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Objectives: To describe treatment discontinuation among postmenopausal 
women initiating denosumab or monthly oBPs in routine clinical practice in 
Bulgaria. MethOds: This retrospective chart review, conducted in 12 Bulgarian 
endocrinology or rheumatology practices, included postmenopausal women ≥ 50 
years old initiating denosumab or monthly oBPs between 1-Oct-2011 and 30-Sep-
2012, followed up to 24 months after treatment initiation. For both denosumab and 
monthly oBPs, discontinuation date was taken from the patients’ medical records 
(including any switch to another treatment/dosing regimen). If no such date was 
recorded, patients’ were assumed to have continued on treatment. Denosumab per-
sistence at 12, 18 and 24 months was defined as receiving the subsequent injection 6 
months +60-days after the previous injection. Persistence to monthly oBPs could not 
be calculated. Results: A total of 224 women initiating denosumab and 217 initiat-
ing monthly oBPs met the inclusion criteria. Of these, 57 (25%) initiating denosumab 
and 38 (18%) initiating monthly oBPs had experienced ≥ 1 prior OP fracture; 3 (1.3%) 
initiating denosumab and 8 (3.7%) initiating monthly oBPs experienced ≥ 1 OP fracture 
during the follow-up period. At treatment initiation, mean (SD) BMD T-scores for the 
denosumab and oBPs groups were -3.2 (±0.65) and -3.0 (±0.57) at the lumbar spine, -3.2 
(±0.69) and -2.8 (±0.73) at the total hip and -2.6 (±0.71) and -2.4 (±0.77) at the femoral 
neck. Within the 24-month follow-up, 4.5% of women initiating denosumab and 56.2% 
initiating monthly oBPs discontinued treatment; median (interquartile range) time 
to discontinuation, 729.0 (728.3„Ÿ729.0) and 367.0 (354.0„Ÿ484.8) days, respectively. 
Denosumab persistence was 100%, 99.1% and 98.7% at 12, 18 and 24 months, respec-
between the first and second courses to 23.9 weeks between the sixth and seventh 
courses. Subgroup analyses performed in 115 patients receiving rituximab in line 
with National Institute for Health and Care Excellence (NICE) guidance, i.e. after 
prior biologic therapy, demonstrated that dispensing frequency in this group did 
not differ markedly from the whole cohort. cOnclusiOns: The findings of this 
analysis show that long-term rituximab use in the National Health Service differs 
from that assumed by NICE in previous appraisals of biologics in RA, with possible 
implications for future assessments of cost-effectiveness.
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Objectives: To determine 12-month persistency rates for five commonly-used 
anti-inflammatory biologic agents and identify cost and patient characteristics 
associated with persistency. MethOds: Using an administrative claims database 
for > 30 U.S. commercial health plans (9.2 million members), we identified patients 
aged ≥ 18 years who had ≥ 1 claim for a biologic anti-inflammatory agent (tocili-
zumab, certolizumab pegol, etanercept, adalimumab or infliximab) in 2012 or 2013 
and were continuously enrolled for ≥ 15 months after the initial claim date. We 
determined rates of 12-month persistency overall and by drug, diagnostic indication, 
comorbidity count, route of drug administration, and copayment level. Results: 
A total of 15,834 patients met study criteria. Twelve-month persistency rates were 
70.7% among all patients and 51.5% among patients new to therapy. Persistency was 
highest for infliximab (82.3%), followed by adalimumab (66.1%), certolizumab pegol 
(65.5%), etanercept (65.1%), and tocilizumab (60.6%) (P< 0.001). Higher persistency 
was observed for drugs administered intravenously (81.2%) versus subcutaneously 
(65.6%) (P< 0.01). Persistency was higher in patients with Crohn’s disease/ulcera-
tive colitis (79.1%) than in patients with rheumatoid arthritis (67.0%) or psoriatic 
conditions (61.4%) (P< 0.01) and was also higher in patients with no comorbidities 
than in those with 1 or ≥ 2 (P< 0.01). Highest persistency was observed for patients 
with a mean plan copayment of $50 to < $100, followed by $0 to< $50, $100 to < $300, 
and ≥ $300 (P< 0.01). This trend was observed irrespective of intravenous or subcu-
taneous route of administration. cOnclusiOns: Twelve-month persistency with 
anti-inflammatory biologic agents was highest in patients with Crohn’s disease 
and lower in patients new to therapy and in those with comorbidities. Persistency 
was higher for drugs administered intravenously versus subcutaneously. Although 
the relationship between persistency and cost-sharing was not linear, copayments 
≥ $300 were associated with lowest persistency. Patient and plan characteristics 
should be considered in efforts to improve patient adherence to therapy.
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Objectives: Non-adherence to treatment represents an important public health 
problem. Little is known about the frequency with which patients fail to fill initial 
prescriptions (“primary non-adherence”) and its predictors. Our aim was to esti-
mate primary non-adherence to antiosteoporotic treatment and its associated fac-
tors. MethOds: Prospective cohort study comprising men and women ≥ 50 years 
(ESOSVAL cohort) who started antiosteoporotic treatment between 2009 and 2011. 
Data were obtained by linking diverse electronic health records of the Valencia region, 
which allows the differentiation between prescriptions (what the doctor prescribed) 
and dispensing (what the patient fills from the pharmacy) at individual level. A 
descriptive analysis was performed according to primary non-adherence and a mul-
tivariable logistic regression analysis to assess factors associated (patient characteris-
tics and medication related covariates) with primary non-adherence. Results: From 
2260 treated patients of the ESOSVAL cohort 712 (31.5%) were new users. Of those, 80% 
were female, mean age 65.4 (64.7-66.1), 22.3% had previous osteoporotic fracture, and 
22.2% had a 10-year risk of hip fracture ≥ 3. Most of the patients (84.1%) were treated 
with bisphosphonates. Regarding primary non-adherence, 6.5% of patients did not fill 
their first prescription at the pharmacy. These patients were more likely to be younger, 
to use medications that decrease bone mass, to have concomitant medications, to 
have high risk of hip fracture (assessed by FRAX), and hospitalizations in the last year. 
Factors independently associated with primary non-adherence were being over 65 
years old (OR:0.29; CI95%:0.13;0.64) compared to the 50-65 year-old age stratum and 
polypharmacy (OR:0.45; CI95%: 0.24;0.86). cOnclusiOns: Primary non-adherence 
was substantial although lower than that observed in other therapeutic areas. Very 
few characteristics were independently associated with primary non-adherence. Our 
findings suggest that those at higher risk for osteoporotic fracture and older were 
more likely to be non-adherent. Further research is needed regarding primary non-
adherence predictors.
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